Cite
Cost Savings of Expedited Care with Upfront Next-Generation Sequencing Testing versus Single-Gene Testing among Patients with Metastatic Non-Small Cell Lung Cancer Based on Current Canadian Practices.
MLA
Sheffield, Brandon S., et al. “Cost Savings of Expedited Care with Upfront Next-Generation Sequencing Testing versus Single-Gene Testing among Patients with Metastatic Non-Small Cell Lung Cancer Based on Current Canadian Practices.” Current Oncology (Toronto, Ont.), vol. 30, no. 2, Feb. 2023, pp. 2348–65. EBSCOhost, https://doi.org/10.3390/curroncol30020180.
APA
Sheffield, B. S., Eaton, K., Emond, B., Lafeuille, M.-H., Hilts, A., Lefebvre, P., Morrison, L., Stevens, A. L., Ewara, E. M., & Cheema, P. (2023). Cost Savings of Expedited Care with Upfront Next-Generation Sequencing Testing versus Single-Gene Testing among Patients with Metastatic Non-Small Cell Lung Cancer Based on Current Canadian Practices. Current Oncology (Toronto, Ont.), 30(2), 2348–2365. https://doi.org/10.3390/curroncol30020180
Chicago
Sheffield, Brandon S, Kiefer Eaton, Bruno Emond, Marie-Hélène Lafeuille, Annalise Hilts, Patrick Lefebvre, Laura Morrison, Andrea L Stevens, Emmanuel M Ewara, and Parneet Cheema. 2023. “Cost Savings of Expedited Care with Upfront Next-Generation Sequencing Testing versus Single-Gene Testing among Patients with Metastatic Non-Small Cell Lung Cancer Based on Current Canadian Practices.” Current Oncology (Toronto, Ont.) 30 (2): 2348–65. doi:10.3390/curroncol30020180.